APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rifaximin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Rifaximin Market Outlook and Growth Opportunities 2026

22 December 2025199 pages

Choose your research edition.

Industry ResearchRifaximin Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Rifaximin Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Rifaximin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rifaximin Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Rifaximin Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Rifaximin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Rifaximin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Rifaximin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rifaximin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Rifaximin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Rifaximin market include Texas Pharmaceuticals, STERIS PHARMA, Soigner Pharma, Salix Pharmaceuticals and Cassopeia Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Rifaximin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Rifaximin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rifaximin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rifaximin market size, projected growth trends, production technologies, key applications, and end-use industries.

Rifaximin Segment by Company

Texas Pharmaceuticals

STERIS PHARMA

Soigner Pharma

Salix Pharmaceuticals

Cassopeia Pharmaceuticals

Rifaximin Segment by Type

200 mg Tablets

550 mg Tablets

Rifaximin Segment by Application

Hospital

Drug store

Rifaximin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Rifaximin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Rifaximin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Rifaximin significant trends, drivers, influence factors in global and regions.

6. To analyze Rifaximin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rifaximin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rifaximin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rifaximin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rifaximin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rifaximin industry.

Chapter 3: Detailed analysis of Rifaximin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Rifaximin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Rifaximin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Rifaximin Industry Trends Table 2. Rifaximin Industry Drivers Table 3. Rifaximin Industry Opportunities and Challenges Table 4. Rifaximin Industry Restraints Table 5. Global Rifaximin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Rifaximin Revenue Share by Company (2021-2026) Table 7. Global Rifaximin Sales Volume by Company (k units) & (2021-2026) Table 8. Global Rifaximin Sales Volume Share by Company (2021-2026) Table 9. Global Rifaximin Average Price (US$/unit) of Company (2021-2026) Table 10. Global Rifaximin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Rifaximin Key Company Manufacturing Base & Headquarters Table 12. Global Rifaximin Company, Product Type & Application Table 13. Global Rifaximin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Rifaximin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 200 mg Tablets Table 18. Significant Companies of 550 mg Tablets Table 19. Global Rifaximin Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Rifaximin Sales Volume by Type (2021-2026) & (k units) Table 21. Global Rifaximin Sales Volume by Type (2027-2032) & (k units) Table 22. Global Rifaximin Sales Volume Share by Type (2021-2026) Table 23. Global Rifaximin Sales Volume Share by Type (2027-2032) Table 24. Global Rifaximin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Rifaximin Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Rifaximin Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Rifaximin Sales Value Share by Type (2021-2026) Table 28. Global Rifaximin Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Drug store Table 31. Global Rifaximin Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Rifaximin Sales Volume by Application (2021-2026) & (k units) Table 33. Global Rifaximin Sales Volume by Application (2027-2032) & (k units) Table 34. Global Rifaximin Sales Volume Share by Application (2021-2026) Table 35. Global Rifaximin Sales Volume Share by Application (2027-2032) Table 36. Global Rifaximin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Rifaximin Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Rifaximin Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Rifaximin Sales Value Share by Application (2021-2026) Table 40. Global Rifaximin Sales Value Share by Application (2027-2032) Table 41. Global Rifaximin Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Rifaximin Sales by Region (2021-2026) & (k units) Table 43. Global Rifaximin Sales Market Share by Region (2021-2026) Table 44. Global Rifaximin Sales by Region (2027-2032) & (k units) Table 45. Global Rifaximin Sales Market Share by Region (2027-2032) Table 46. Global Rifaximin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Rifaximin Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Rifaximin Sales Value Share by Region (2021-2026) Table 49. Global Rifaximin Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Rifaximin Sales Value Share by Region (2027-2032) Table 51. Global Rifaximin Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Rifaximin Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Rifaximin Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Rifaximin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Rifaximin Sales by Country (2021-2026) & (k units) Table 56. Global Rifaximin Sales Market Share by Country (2021-2026) Table 57. Global Rifaximin Sales by Country (2027-2032) & (k units) Table 58. Global Rifaximin Sales Market Share by Country (2027-2032) Table 59. Global Rifaximin Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Rifaximin Sales Value Market Share by Country (2021-2026) Table 61. Global Rifaximin Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Rifaximin Sales Value Market Share by Country (2027-2032) Table 63. Texas Pharmaceuticals Company Information Table 64. Texas Pharmaceuticals Business Overview Table 65. Texas Pharmaceuticals Rifaximin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Texas Pharmaceuticals Rifaximin Product Portfolio Table 67. Texas Pharmaceuticals Recent Development Table 68. STERIS PHARMA Company Information Table 69. STERIS PHARMA Business Overview Table 70. STERIS PHARMA Rifaximin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. STERIS PHARMA Rifaximin Product Portfolio Table 72. STERIS PHARMA Recent Development Table 73. Soigner Pharma Company Information Table 74. Soigner Pharma Business Overview Table 75. Soigner Pharma Rifaximin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Soigner Pharma Rifaximin Product Portfolio Table 77. Soigner Pharma Recent Development Table 78. Salix Pharmaceuticals Company Information Table 79. Salix Pharmaceuticals Business Overview Table 80. Salix Pharmaceuticals Rifaximin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Salix Pharmaceuticals Rifaximin Product Portfolio Table 82. Salix Pharmaceuticals Recent Development Table 83. Cassopeia Pharmaceuticals Company Information Table 84. Cassopeia Pharmaceuticals Business Overview Table 85. Cassopeia Pharmaceuticals Rifaximin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Cassopeia Pharmaceuticals Rifaximin Product Portfolio Table 87. Cassopeia Pharmaceuticals Recent Development Table 88. Key Raw Materials Table 89. Raw Materials Key Suppliers Table 90. Rifaximin Distributors List Table 91. Rifaximin Customers List Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Rifaximin Product Image Figure 2. Global Rifaximin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rifaximin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Rifaximin Sales (2021-2032) & (k units) Figure 5. Global Rifaximin Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Rifaximin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 200 mg Tablets Image Figure 10. 550 mg Tablets Image Figure 11. Global Rifaximin Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Rifaximin Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Rifaximin Sales Volume Share by Type (2021-2032) Figure 14. Global Rifaximin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Rifaximin Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Rifaximin Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Drug store Image Figure 19. Global Rifaximin Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Rifaximin Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Rifaximin Sales Volume Share by Application (2021-2032) Figure 22. Global Rifaximin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Rifaximin Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Rifaximin Sales Value Share by Application (2021-2032) Figure 25. Global Rifaximin Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Rifaximin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Rifaximin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Rifaximin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Rifaximin Sales Value (2021-2032) & (US$ Million) Figure 30. North America Rifaximin Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Rifaximin Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Rifaximin Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Rifaximin Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Rifaximin Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Rifaximin Sales Value (2021-2032) & (US$ Million) Figure 36. South America Rifaximin Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Rifaximin Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Rifaximin Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Rifaximin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Rifaximin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Rifaximin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Rifaximin Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Rifaximin Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 200 mg Tablets
  • 550 mg Tablets
Applications
  • Hospital
  • Drug store
Companies covered
  • Texas Pharmaceuticals
  • STERIS PHARMA
  • Soigner Pharma
  • Salix Pharmaceuticals
  • Cassopeia Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Rifaximin Sales Value (2021-2032)
  4. 1.2.2 Global Rifaximin Sales Volume (2021-2032)
  5. 1.2.3 Global Rifaximin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Rifaximin Market Dynamics
  1. 2.1 Rifaximin Industry Trends
  2. 2.2 Rifaximin Industry Drivers
  3. 2.3 Rifaximin Industry Opportunities and Challenges
  4. 2.4 Rifaximin Industry Restraints
3 Rifaximin Market by Company
  1. 3.1 Global Rifaximin Company Revenue Ranking in 2025
  2. 3.2 Global Rifaximin Revenue by Company (2021-2026)
  3. 3.3 Global Rifaximin Sales Volume by Company (2021-2026)
  4. 3.4 Global Rifaximin Average Price by Company (2021-2026)
  5. 3.5 Global Rifaximin Company Ranking (2024-2026)
  6. 3.6 Global Rifaximin Company Manufacturing Base and Headquarters
  7. 3.7 Global Rifaximin Company Product Type and Application
  8. 3.8 Global Rifaximin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Rifaximin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Rifaximin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Rifaximin Market by Type
  1. 4.1 Rifaximin Type Introduction
  2. 4.1.1 200 mg Tablets
  3. 4.1.2 550 mg Tablets
  4. 4.2 Global Rifaximin Sales Volume by Type
  5. 4.2.1 Global Rifaximin Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Rifaximin Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Rifaximin Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Rifaximin Sales Value by Type
  9. 4.3.1 Global Rifaximin Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Rifaximin Sales Value by Type (2021-2032)
  11. 4.3.3 Global Rifaximin Sales Value Share by Type (2021-2032)
5 Rifaximin Market by Application
  1. 5.1 Rifaximin Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drug store
  4. 5.2 Global Rifaximin Sales Volume by Application
  5. 5.2.1 Global Rifaximin Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Rifaximin Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Rifaximin Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Rifaximin Sales Value by Application
  9. 5.3.1 Global Rifaximin Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Rifaximin Sales Value by Application (2021-2032)
  11. 5.3.3 Global Rifaximin Sales Value Share by Application (2021-2032)
6 Rifaximin Regional Sales and Value Analysis
  1. 6.1 Global Rifaximin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rifaximin Sales by Region (2021-2032)
  3. 6.2.1 Global Rifaximin Sales by Region: 2021-2026
  4. 6.2.2 Global Rifaximin Sales by Region (2027-2032)
  5. 6.3 Global Rifaximin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Rifaximin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Rifaximin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Rifaximin Sales Value by Region (2027-2032)
  9. 6.5 Global Rifaximin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Rifaximin Sales Value (2021-2032)
  12. 6.6.2 North America Rifaximin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Rifaximin Sales Value (2021-2032)
  15. 6.7.2 Europe Rifaximin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Rifaximin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Rifaximin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Rifaximin Sales Value (2021-2032)
  21. 6.9.2 South America Rifaximin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Rifaximin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Rifaximin Sales Value Share by Country, 2025 VS 2032
7 Rifaximin Country-level Sales and Value Analysis
  1. 7.1 Global Rifaximin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Rifaximin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Rifaximin Sales by Country (2021-2032)
  4. 7.3.1 Global Rifaximin Sales by Country (2021-2026)
  5. 7.3.2 Global Rifaximin Sales by Country (2027-2032)
  6. 7.4 Global Rifaximin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Rifaximin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Rifaximin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Rifaximin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Rifaximin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Rifaximin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Rifaximin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Rifaximin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Rifaximin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Rifaximin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Rifaximin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Rifaximin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Rifaximin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Rifaximin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Rifaximin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Rifaximin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Rifaximin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Rifaximin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Rifaximin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Rifaximin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Rifaximin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Rifaximin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Rifaximin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Rifaximin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Rifaximin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Rifaximin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Rifaximin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Rifaximin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Rifaximin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Rifaximin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Rifaximin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Rifaximin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Rifaximin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Rifaximin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Rifaximin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Rifaximin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Rifaximin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Rifaximin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Rifaximin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Rifaximin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Rifaximin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Rifaximin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Rifaximin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Rifaximin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Rifaximin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Rifaximin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Rifaximin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Rifaximin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Rifaximin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Rifaximin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Rifaximin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Rifaximin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Rifaximin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Rifaximin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Rifaximin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Rifaximin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Rifaximin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Rifaximin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Rifaximin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Rifaximin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Rifaximin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Rifaximin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Rifaximin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Rifaximin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Rifaximin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Rifaximin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Rifaximin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Rifaximin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Rifaximin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Rifaximin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Rifaximin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Rifaximin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Rifaximin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Rifaximin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Rifaximin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Rifaximin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Rifaximin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Rifaximin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Rifaximin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Rifaximin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Rifaximin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Rifaximin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Rifaximin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Rifaximin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Rifaximin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Rifaximin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Rifaximin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Texas Pharmaceuticals
  2. 8.1.1 Texas Pharmaceuticals Company Information
  3. 8.1.2 Texas Pharmaceuticals Business Overview
  4. 8.1.3 Texas Pharmaceuticals Rifaximin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Texas Pharmaceuticals Rifaximin Product Portfolio
  6. 8.1.5 Texas Pharmaceuticals Recent Developments
  7. 8.2 STERIS PHARMA
  8. 8.2.1 STERIS PHARMA Company Information
  9. 8.2.2 STERIS PHARMA Business Overview
  10. 8.2.3 STERIS PHARMA Rifaximin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 STERIS PHARMA Rifaximin Product Portfolio
  12. 8.2.5 STERIS PHARMA Recent Developments
  13. 8.3 Soigner Pharma
  14. 8.3.1 Soigner Pharma Company Information
  15. 8.3.2 Soigner Pharma Business Overview
  16. 8.3.3 Soigner Pharma Rifaximin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Soigner Pharma Rifaximin Product Portfolio
  18. 8.3.5 Soigner Pharma Recent Developments
  19. 8.4 Salix Pharmaceuticals
  20. 8.4.1 Salix Pharmaceuticals Company Information
  21. 8.4.2 Salix Pharmaceuticals Business Overview
  22. 8.4.3 Salix Pharmaceuticals Rifaximin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Salix Pharmaceuticals Rifaximin Product Portfolio
  24. 8.4.5 Salix Pharmaceuticals Recent Developments
  25. 8.5 Cassopeia Pharmaceuticals
  26. 8.5.1 Cassopeia Pharmaceuticals Company Information
  27. 8.5.2 Cassopeia Pharmaceuticals Business Overview
  28. 8.5.3 Cassopeia Pharmaceuticals Rifaximin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Cassopeia Pharmaceuticals Rifaximin Product Portfolio
  30. 8.5.5 Cassopeia Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Rifaximin Value Chain Analysis
  2. 9.1.1 Rifaximin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Rifaximin Sales Mode & Process
  6. 9.2 Rifaximin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Rifaximin Distributors
  9. 9.2.3 Rifaximin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst